Selected Publications

Connor MP, Prathapa N, Frey NV, Gill SI, Hexner EO, Bruno XJ, Lai CE, Loren AW, Luger SM, Matthews AH, McCurdy SR, Perl AE, Porter DL, Zeringue A, Oved JH, Olson TS, Pratz KW, Babushok DV: Hypomethylating agents are associated with high rates of hematologic toxicity in patients with secondary myeloid neoplasms developing after acquired aplastic anemia. Haematologica Apr 2024.

Vakilpour A, Lefebvre B, Lai C, Scherrer-Crosbie M: Heartbreaker: Detection and prevention of cardiotoxicity in hematological malignancies. Blood Mar 2024.

Matthews A, Fenu E, Skuli SJ, Harris JC, Lai C: Immunohistochemistry-based detection of TP53 mutations in acute myeloid leukemia: a promising high sensitivity diagnostic approach. Leuk Lymphoma Mar 2024.

Solomon SR, Powell BL, Koprivnikar J, Lai C, Male H, Michaelis LC, Newell LF, Sanford D, Jenkins J, Zelaya A, Coppola S, Faderl S, Walter RB: CPX-351 pharmacokinetics and safety in adults with hematologic malignancies and renal function impairment: phase 1 trial. Cancers (Basel) Feb 2024.

Chan B, Taylor AO, Doucette K, Ma X, Ahn J, Lai C.: Influence of Income and Education on Palliative Care in Acute Myeloid Leukemia Using the NCDB. J Pain Symptom Manage Jan 2024.

Vakilpour A, Lefebvre B, Lai C, Scherrer-Crosbie M.: Heartbreaker: Detection and prevention of cardiotoxicity in hematological malignancies. Blood Rev. Dec 2023.

Williams LS, Williams KM, Gillis N, Bolton K, Damm F, Deuitch NT, Farhadfar N, Gergis U, Keel SB, Michelis FV, Panch SR, Porter CC, Sucheston-Campbell L, Tamari R, Stefanski HE, Godley LA, Lai C: Donor-Derived Malignancy and Transplantation Morbidity: Risks of Patient and Donor Genetics in Allogeneic Hematopoietic Stem Cell Transplantation. Transplant Cell Ther Oct 2023.

Matthews AH, Perl AE, Luger SM, Gill SI, Lai C, Porter DL, Skuli S, Bruno XJ, Carroll MP, Freyer CW, Carulli A, Babushok DV, Frey NV, Hexner EO, Martin ME, McCurdy SR, Stadtmauer EA, Loren AW, Paralkar VR, Maillard IP, Pratz KW: Real-world effectiveness of intensive chemotherapy with 7&3 versus venetoclax and hypomethylating agent in acute myeloid leukemia. Am J Hematol Jun 2023.

Keith Pratz, Catherine Lai, Brian A Jones, Courtney DiNardo, Cat N. Bui, Rajesh Kamalakar, Jalaja Potluri, Wei-han Chang, Rohini Sen, Thomas W. Leblanc: VENETOCLAX PLUS AZACITIDINE DELAYS DETERIORATION OF HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA: VIALE-A LONG-TERM FOLLOW UP. European Hematology Association - 28th Congress for Oral Presentation June 2023.

Franco S, Geng X, Korostyshevskiy V, Karp JE, Lai C.: Systematic review and meta-analysis: Prognostic impact of time from diagnosis to treatment in patients with acute myeloid leukemia Cancer May 2023.